Vooralsnog geen aanwijzingen voor onveiligheid van de behandeling met groeihormoon van volwassen patiënten met groeihormoondeficiëntie

- Although more than 100,000 patients worldwide are estimated to have received growth-hormone treatment, there are still widespread doubts about the safety aspects of growth-hormone treatment of adults with growth-hormone deficiency (GHD).

- The available data are scarce and the follow-up time is short.

- The data do not suggest that growth-hormone treatment increases the incidence or regrowth of pituitary adenomas in adults with GHD.

- Equally there are no data which suggest that growth-hormone treatment of adults with GHD increases the incidence of cancer, provided that concentrations of the insulin-like growth factor I (IGF-I) achieved in the blood remain within the normal range for the age of that patient.

- No increase in diabetes mellitus has been reported following the introduction of growth-hormone treatment in adult GHD patients. Insulin sensitivity does not appear to change in GHD patients on growth-hormone treatment as long as relatively low physiological doses of growth hormone are used.

- Whether growth-hormone therapy in adult patients with GHD will prove safe in the long term remains to be established.